daclatasvir + asunaprevir + beclabuvir

**Generic Name:** daclatasvir/asunaprevir/beclabuvir  
**Abbreviation:** DCV/ASV/BCV or DCV-TRIO  
**Drug Class:** Multi-Class Combination Drugs  
**Company:** Bristol-Myers Squibb  
**Approval Status:** Phase III  
**Generic Version Available:** No  
**Experimental Code:** BMS 790052 + BMS 650032 + BMS 791325

---

**Drug Indication**

This drug regimen has not yet been FDA-approved or reviewed for inclusion in the AASLD/IDSA list of recommended HCV treatments.

---

**General Info**

- This drug regimen is an experimental HCV medication, currently in Phase III clinical trials.  
- DCV-TRIO is a fixed-dose regimen containing one currently approved HCV medication (daclatasvir) and two experimental medications (asunaprevir and beclabuvir). Daclatasvir is an approved NS5A replication complex inhibitor; asunaprevir is an NS3 protease inhibitor; beclabuvir is a non-nucleoside NS5B polymerase inhibitor.  
- DCV-TRIO is being tested for the treatment of chronic hepatitis C infection in adults for genotypes 1, 4, and 6.

---

**Dosage**

**Adult Dose:** In clinical trials, subjects received a twice-daily, fixed-dose regimen of daclatasvir (30 mg), asunaprevir (200 mg) and beclabuvir (75 mg).  
**Pediatric Dose:** N/A
Dosing Info: N/A

Side Effects

The most common side effects reported in clinical trials were headache, diarrhea, fatigue and nausea.

Last Reviewed: March 5, 2019